Samjin Pharmaceuticals Co., Ltd.
KSC: 005500.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kyu Seok Cho
- Employees
- 586
- Headquarters
- Seoul, South Korea
- IPO year
- 2005
- Market cap
- ₩223B
- Website
- https://www.samjinpharm.co.kr
Loading 005500…
Loading profile data…Frequently asked questions about 005500
What does Samjin Pharmaceuticals Co., Ltd. (005500.KS) do?
Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stag...
Where does 005500.KS trade?
Samjin Pharmaceuticals Co., Ltd. (005500.KS) trades on the Korea Exchange.
What sector is 005500.KS in?
Samjin Pharmaceuticals Co., Ltd. (005500.KS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Samjin Pharmaceuticals Co., Ltd.?
Kyu Seok Cho is the chief executive officer of Samjin Pharmaceuticals Co., Ltd. (005500.KS).
Where is Samjin Pharmaceuticals Co., Ltd. headquartered?
Samjin Pharmaceuticals Co., Ltd. is headquartered in South Korea.
Does 005500.KS pay a dividend?
Yes — Samjin Pharmaceuticals Co., Ltd. (005500.KS) paid a trailing twelve-month dividend of KRW 800.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 005500.KS go public?
Samjin Pharmaceuticals Co., Ltd. (005500.KS) completed its initial public offering in 2005.